Studies by Nakagawa et al. have examined the dual blockade of EGFR and VEGF pathways in EGFR-mutated metastatic NSCLC, with phase three trials of EGFR TKI combined with ramucirumab showing positive outcomes on progression-free survival [57]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.